Oncology Institute (TOIIW) Net Income towards Common Stockholders (2020 - 2026)

Oncology Institute has reported Net Income towards Common Stockholders for 7 years, with the latest figure at -$2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 86.97% year-over-year to -$2.1 million; the trailing twelve-month figure through Mar 2026 stood at -$36.3 million (up 31.29% YoY), and the FY2025 full-year result was -$50.3 million, up 5.09% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$2.1 million, up from -$6.4 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $19.3 million in Q1 2022, with the low at -$30.0 million in Q1 2023.
• Historically, Net Income towards Common Stockholders has averaged -$11.3 million across 5 years, with a median of -$13.2 million in 2024.
• The largest YoY upside for Net Income towards Common Stockholders was 238.35% in 2022 against a maximum downside of 673.67% in 2022.
• Oncology Institute's Net Income towards Common Stockholders stood at -$11.0 million in 2022, then plunged by 70.38% to -$18.8 million in 2023, then jumped by 42.27% to -$10.8 million in 2024, then soared by 40.63% to -$6.4 million in 2025, then surged by 67.42% to -$2.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$2.1 million (Q1 2026), -$6.4 million (Q4 2025), and -$13.8 million (Q3 2025), per Business Quant data.